Shionogi receives award through BARDA’s RRPV to advance long-acting formulation of S-892216, an antiviral for COVID-19 pre-exposure prophylaxis in at-risk populations
OSAKA, Japan — (BUSINESS WIRE) — Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a $375 million project agreement through the Rapid